nodes	percent_of_prediction	percent_of_DWPC	metapath
Metolazone—CA7—colon cancer	0.827	1	CbGaD
Metolazone—CA5A—Reversible hydration of carbon dioxide—CA7—colon cancer	0.0211	0.219	CbGpPWpGaD
Metolazone—CA5B—Reversible hydration of carbon dioxide—CA7—colon cancer	0.0197	0.204	CbGpPWpGaD
Metolazone—CA12—Reversible hydration of carbon dioxide—CA7—colon cancer	0.0182	0.189	CbGpPWpGaD
Metolazone—CA4—Reversible hydration of carbon dioxide—CA7—colon cancer	0.0145	0.151	CbGpPWpGaD
Metolazone—CA9—Reversible hydration of carbon dioxide—CA7—colon cancer	0.0117	0.122	CbGpPWpGaD
Metolazone—Indapamide—CA7—colon cancer	0.00287	0.537	CrCbGaD
Metolazone—Chlorthalidone—CA7—colon cancer	0.00247	0.463	CrCbGaD
Metolazone—Hypovolaemia—Irinotecan—colon cancer	0.00228	0.036	CcSEcCtD
Metolazone—CA9—gall bladder—colon cancer	0.00149	0.195	CbGeAlD
Metolazone—Hypomagnesaemia—Irinotecan—colon cancer	0.00111	0.0175	CcSEcCtD
Metolazone—CA9—Regulation of gene expression by Hypoxia-inducible Factor—EP300—colon cancer	0.00108	0.0112	CbGpPWpGaD
Metolazone—CA9—Regulation of gene expression by Hypoxia-inducible Factor—VEGFA—colon cancer	0.00102	0.0106	CbGpPWpGaD
Metolazone—Skin necrosis—Methotrexate—colon cancer	0.00101	0.0159	CcSEcCtD
Metolazone—Peripheral coldness—Capecitabine—colon cancer	0.000994	0.0157	CcSEcCtD
Metolazone—Venous thrombosis—Capecitabine—colon cancer	0.000877	0.0138	CcSEcCtD
Metolazone—CA7—renal system—colon cancer	0.000816	0.107	CbGeAlD
Metolazone—SLC12A3—renal system—colon cancer	0.0008	0.105	CbGeAlD
Metolazone—Hyperuricaemia—Vincristine—colon cancer	0.000783	0.0123	CcSEcCtD
Metolazone—CA9—HIF-1-alpha transcription factor network—HNF4A—colon cancer	0.00077	0.008	CbGpPWpGaD
Metolazone—CA5A—liver—colon cancer	0.00075	0.098	CbGeAlD
Metolazone—Hypomagnesaemia—Capecitabine—colon cancer	0.000745	0.0117	CcSEcCtD
Metolazone—Blood uric acid increased—Vincristine—colon cancer	0.00074	0.0117	CcSEcCtD
Metolazone—Neuropathy—Vincristine—colon cancer	0.000682	0.0107	CcSEcCtD
Metolazone—Hypercalcaemia—Capecitabine—colon cancer	0.000682	0.0107	CcSEcCtD
Metolazone—CA7—digestive system—colon cancer	0.000669	0.0875	CbGeAlD
Metolazone—Throat sore—Capecitabine—colon cancer	0.000657	0.0103	CcSEcCtD
Metolazone—Oropharyngeal discomfort—Capecitabine—colon cancer	0.000651	0.0103	CcSEcCtD
Metolazone—CA9—digestive system—colon cancer	0.000588	0.0769	CbGeAlD
Metolazone—Petechiae—Capecitabine—colon cancer	0.000576	0.00907	CcSEcCtD
Metolazone—Photosensitivity—Fluorouracil—colon cancer	0.00056	0.00883	CcSEcCtD
Metolazone—Swelling—Fluorouracil—colon cancer	0.000558	0.00878	CcSEcCtD
Metolazone—CA12—renal system—colon cancer	0.00053	0.0693	CbGeAlD
Metolazone—Hyponatraemia—Vincristine—colon cancer	0.000529	0.00834	CcSEcCtD
Metolazone—Oropharyngeal pain—Capecitabine—colon cancer	0.000521	0.0082	CcSEcCtD
Metolazone—Hyponatraemia—Irinotecan—colon cancer	0.000516	0.00812	CcSEcCtD
Metolazone—Nocturia—Capecitabine—colon cancer	0.00051	0.00804	CcSEcCtD
Metolazone—Lethargy—Fluorouracil—colon cancer	0.000502	0.00791	CcSEcCtD
Metolazone—CA9—HIF-1-alpha transcription factor network—ABCB1—colon cancer	0.000481	0.00499	CbGpPWpGaD
Metolazone—CA9—Cellular response to hypoxia—EP300—colon cancer	0.000476	0.00494	CbGpPWpGaD
Metolazone—Orthostatic hypotension—Irinotecan—colon cancer	0.000469	0.00739	CcSEcCtD
Metolazone—Hypokalaemia—Irinotecan—colon cancer	0.000467	0.00736	CcSEcCtD
Metolazone—Cramp muscle—Irinotecan—colon cancer	0.000462	0.00729	CcSEcCtD
Metolazone—Skin exfoliation—Capecitabine—colon cancer	0.000452	0.00712	CcSEcCtD
Metolazone—Dry skin—Fluorouracil—colon cancer	0.000451	0.0071	CcSEcCtD
Metolazone—CA9—Cellular response to hypoxia—VEGFA—colon cancer	0.000451	0.00468	CbGpPWpGaD
Metolazone—Abdominal distension—Irinotecan—colon cancer	0.000447	0.00704	CcSEcCtD
Metolazone—Neuropathy—Capecitabine—colon cancer	0.000445	0.007	CcSEcCtD
Metolazone—Pancreatitis—Irinotecan—colon cancer	0.000435	0.00686	CcSEcCtD
Metolazone—CA12—digestive system—colon cancer	0.000435	0.0569	CbGeAlD
Metolazone—Petechiae—Methotrexate—colon cancer	0.000428	0.00675	CcSEcCtD
Metolazone—CA5A—Metabolism—CA7—colon cancer	0.000428	0.00445	CbGpPWpGaD
Metolazone—Erectile dysfunction—Vincristine—colon cancer	0.00042	0.00661	CcSEcCtD
Metolazone—Photosensitivity reaction—Vincristine—colon cancer	0.000416	0.00655	CcSEcCtD
Metolazone—CA5B—Metabolism—CA7—colon cancer	0.0004	0.00415	CbGpPWpGaD
Metolazone—Neuropathy peripheral—Vincristine—colon cancer	0.000398	0.00628	CcSEcCtD
Metolazone—Photosensitivity—Capecitabine—colon cancer	0.000391	0.00617	CcSEcCtD
Metolazone—Swelling—Capecitabine—colon cancer	0.00039	0.00614	CcSEcCtD
Metolazone—Photosensitivity reaction—Fluorouracil—colon cancer	0.000388	0.00611	CcSEcCtD
Metolazone—Vascular purpura—Capecitabine—colon cancer	0.000384	0.00605	CcSEcCtD
Metolazone—Hyperuricaemia—Methotrexate—colon cancer	0.00038	0.00599	CcSEcCtD
Metolazone—Neuropathy peripheral—Fluorouracil—colon cancer	0.000372	0.00585	CcSEcCtD
Metolazone—CA12—Metabolism—CA7—colon cancer	0.00037	0.00385	CbGpPWpGaD
Metolazone—Blood uric acid increased—Methotrexate—colon cancer	0.000359	0.00566	CcSEcCtD
Metolazone—Epistaxis—Fluorouracil—colon cancer	0.000358	0.00563	CcSEcCtD
Metolazone—Purpura—Capecitabine—colon cancer	0.000357	0.00562	CcSEcCtD
Metolazone—Agranulocytosis—Fluorouracil—colon cancer	0.000354	0.00557	CcSEcCtD
Metolazone—Lethargy—Capecitabine—colon cancer	0.000351	0.00553	CcSEcCtD
Metolazone—Hyponatraemia—Capecitabine—colon cancer	0.000345	0.00544	CcSEcCtD
Metolazone—CA5B—vagina—colon cancer	0.000345	0.045	CbGeAlD
Metolazone—Skin exfoliation—Methotrexate—colon cancer	0.000337	0.0053	CcSEcCtD
Metolazone—CA4—renal system—colon cancer	0.000328	0.0429	CbGeAlD
Metolazone—Chills—Irinotecan—colon cancer	0.000319	0.00502	CcSEcCtD
Metolazone—Dry skin—Capecitabine—colon cancer	0.000315	0.00496	CcSEcCtD
Metolazone—Orthostatic hypotension—Capecitabine—colon cancer	0.000314	0.00495	CcSEcCtD
Metolazone—Hypokalaemia—Capecitabine—colon cancer	0.000313	0.00493	CcSEcCtD
Metolazone—Toxic epidermal necrolysis—Capecitabine—colon cancer	0.000309	0.00488	CcSEcCtD
Metolazone—Back pain—Vincristine—colon cancer	0.000307	0.00484	CcSEcCtD
Metolazone—Flatulence—Irinotecan—colon cancer	0.000305	0.0048	CcSEcCtD
Metolazone—Back pain—Irinotecan—colon cancer	0.000299	0.00471	CcSEcCtD
Metolazone—Abdominal distension—Capecitabine—colon cancer	0.000299	0.00471	CcSEcCtD
Metolazone—Muscle spasms—Irinotecan—colon cancer	0.000297	0.00468	CcSEcCtD
Metolazone—CA4—Metabolism—CA7—colon cancer	0.000295	0.00307	CbGpPWpGaD
Metolazone—Anaemia—Vincristine—colon cancer	0.000294	0.00462	CcSEcCtD
Metolazone—Agitation—Vincristine—colon cancer	0.000292	0.0046	CcSEcCtD
Metolazone—Photosensitivity—Methotrexate—colon cancer	0.000291	0.00459	CcSEcCtD
Metolazone—Ill-defined disorder—Irinotecan—colon cancer	0.000287	0.00452	CcSEcCtD
Metolazone—Anaemia—Irinotecan—colon cancer	0.000286	0.0045	CcSEcCtD
Metolazone—Vertigo—Vincristine—colon cancer	0.000285	0.0045	CcSEcCtD
Metolazone—Abdominal discomfort—Capecitabine—colon cancer	0.000285	0.00449	CcSEcCtD
Metolazone—Leukopenia—Vincristine—colon cancer	0.000284	0.00448	CcSEcCtD
Metolazone—Vision blurred—Fluorouracil—colon cancer	0.000279	0.0044	CcSEcCtD
Metolazone—Malaise—Irinotecan—colon cancer	0.000279	0.00439	CcSEcCtD
Metolazone—Vertigo—Irinotecan—colon cancer	0.000278	0.00438	CcSEcCtD
Metolazone—Syncope—Irinotecan—colon cancer	0.000277	0.00437	CcSEcCtD
Metolazone—Leukopenia—Irinotecan—colon cancer	0.000277	0.00436	CcSEcCtD
Metolazone—Hypertension—Vincristine—colon cancer	0.000274	0.00432	CcSEcCtD
Metolazone—Anaemia—Fluorouracil—colon cancer	0.000274	0.00431	CcSEcCtD
Metolazone—Loss of consciousness—Irinotecan—colon cancer	0.000272	0.00428	CcSEcCtD
Metolazone—Photosensitivity reaction—Capecitabine—colon cancer	0.000271	0.00427	CcSEcCtD
Metolazone—Cough—Irinotecan—colon cancer	0.00027	0.00425	CcSEcCtD
Metolazone—CA4—digestive system—colon cancer	0.000269	0.0352	CbGeAlD
Metolazone—Hyperglycaemia—Capecitabine—colon cancer	0.000268	0.00422	CcSEcCtD
Metolazone—Hypertension—Irinotecan—colon cancer	0.000267	0.00421	CcSEcCtD
Metolazone—Leukopenia—Fluorouracil—colon cancer	0.000265	0.00418	CcSEcCtD
Metolazone—Stevens-Johnson syndrome—Capecitabine—colon cancer	0.000263	0.00414	CcSEcCtD
Metolazone—Lethargy—Methotrexate—colon cancer	0.000261	0.00411	CcSEcCtD
Metolazone—Discomfort—Irinotecan—colon cancer	0.00026	0.0041	CcSEcCtD
Metolazone—Neuropathy peripheral—Capecitabine—colon cancer	0.00026	0.00409	CcSEcCtD
Metolazone—CA5A—Metabolism—CHST5—colon cancer	0.000259	0.00269	CbGpPWpGaD
Metolazone—CA5A—Metabolism—ODC1—colon cancer	0.000259	0.00269	CbGpPWpGaD
Metolazone—Thrombocytopenia—Vincristine—colon cancer	0.000254	0.004	CcSEcCtD
Metolazone—Chest pain—Fluorouracil—colon cancer	0.000252	0.00397	CcSEcCtD
Metolazone—Epistaxis—Capecitabine—colon cancer	0.00025	0.00394	CcSEcCtD
Metolazone—Discomfort—Fluorouracil—colon cancer	0.000249	0.00393	CcSEcCtD
Metolazone—Shock—Irinotecan—colon cancer	0.000248	0.00391	CcSEcCtD
Metolazone—CA4—bone marrow—colon cancer	0.000248	0.0325	CbGeAlD
Metolazone—Agranulocytosis—Capecitabine—colon cancer	0.000247	0.00389	CcSEcCtD
Metolazone—Thrombocytopenia—Irinotecan—colon cancer	0.000247	0.00389	CcSEcCtD
Metolazone—Anorexia—Vincristine—colon cancer	0.000247	0.00389	CcSEcCtD
Metolazone—CA5B—Metabolism—ODC1—colon cancer	0.000242	0.00252	CbGpPWpGaD
Metolazone—CA5B—Metabolism—CHST5—colon cancer	0.000242	0.00252	CbGpPWpGaD
Metolazone—CA7—Metabolism—ODC1—colon cancer	0.000242	0.00252	CbGpPWpGaD
Metolazone—CA7—Metabolism—CHST5—colon cancer	0.000242	0.00252	CbGpPWpGaD
Metolazone—Anorexia—Irinotecan—colon cancer	0.000241	0.00379	CcSEcCtD
Metolazone—CA9—Metabolism—CA7—colon cancer	0.000239	0.00248	CbGpPWpGaD
Metolazone—Hepatitis—Capecitabine—colon cancer	0.000238	0.00375	CcSEcCtD
Metolazone—Thrombocytopenia—Fluorouracil—colon cancer	0.000237	0.00373	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Vincristine—colon cancer	0.000236	0.00372	CcSEcCtD
Metolazone—Insomnia—Vincristine—colon cancer	0.000234	0.00369	CcSEcCtD
Metolazone—Paraesthesia—Vincristine—colon cancer	0.000233	0.00367	CcSEcCtD
Metolazone—Anorexia—Fluorouracil—colon cancer	0.00023	0.00363	CcSEcCtD
Metolazone—Toxic epidermal necrolysis—Methotrexate—colon cancer	0.00023	0.00363	CcSEcCtD
Metolazone—Insomnia—Irinotecan—colon cancer	0.000228	0.0036	CcSEcCtD
Metolazone—Paraesthesia—Irinotecan—colon cancer	0.000227	0.00357	CcSEcCtD
Metolazone—Decreased appetite—Vincristine—colon cancer	0.000225	0.00355	CcSEcCtD
Metolazone—Erythema multiforme—Capecitabine—colon cancer	0.000225	0.00354	CcSEcCtD
Metolazone—Somnolence—Irinotecan—colon cancer	0.000224	0.00354	CcSEcCtD
Metolazone—CA12—Metabolism—CHST5—colon cancer	0.000224	0.00233	CbGpPWpGaD
Metolazone—CA12—Metabolism—ODC1—colon cancer	0.000224	0.00233	CbGpPWpGaD
Metolazone—Fatigue—Vincristine—colon cancer	0.000223	0.00352	CcSEcCtD
Metolazone—CA5B—lymph node—colon cancer	0.000223	0.0291	CbGeAlD
Metolazone—Dyspepsia—Irinotecan—colon cancer	0.000222	0.0035	CcSEcCtD
Metolazone—Tinnitus—Capecitabine—colon cancer	0.000222	0.00349	CcSEcCtD
Metolazone—Pain—Vincristine—colon cancer	0.000222	0.00349	CcSEcCtD
Metolazone—Constipation—Vincristine—colon cancer	0.000222	0.00349	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.00022	0.00347	CcSEcCtD
Metolazone—Decreased appetite—Irinotecan—colon cancer	0.000219	0.00346	CcSEcCtD
Metolazone—CA9—HIF-1-alpha transcription factor network—EP300—colon cancer	0.000219	0.00227	CbGpPWpGaD
Metolazone—Insomnia—Fluorouracil—colon cancer	0.000219	0.00344	CcSEcCtD
Metolazone—Fatigue—Irinotecan—colon cancer	0.000218	0.00343	CcSEcCtD
Metolazone—Paraesthesia—Fluorouracil—colon cancer	0.000217	0.00342	CcSEcCtD
Metolazone—Pancreatitis—Methotrexate—colon cancer	0.000217	0.00342	CcSEcCtD
Metolazone—Constipation—Irinotecan—colon cancer	0.000216	0.0034	CcSEcCtD
Metolazone—Pain—Irinotecan—colon cancer	0.000216	0.0034	CcSEcCtD
Metolazone—Somnolence—Fluorouracil—colon cancer	0.000215	0.00339	CcSEcCtD
Metolazone—Chills—Capecitabine—colon cancer	0.000213	0.00336	CcSEcCtD
Metolazone—Dyspepsia—Fluorouracil—colon cancer	0.000213	0.00335	CcSEcCtD
Metolazone—Abdominal discomfort—Methotrexate—colon cancer	0.000212	0.00334	CcSEcCtD
Metolazone—Gastrointestinal pain—Vincristine—colon cancer	0.000212	0.00334	CcSEcCtD
Metolazone—Decreased appetite—Fluorouracil—colon cancer	0.00021	0.00331	CcSEcCtD
Metolazone—Feeling abnormal—Irinotecan—colon cancer	0.000208	0.00328	CcSEcCtD
Metolazone—CA9—HIF-1-alpha transcription factor network—VEGFA—colon cancer	0.000207	0.00215	CbGpPWpGaD
Metolazone—Pain—Fluorouracil—colon cancer	0.000207	0.00326	CcSEcCtD
Metolazone—Gastrointestinal pain—Irinotecan—colon cancer	0.000206	0.00325	CcSEcCtD
Metolazone—Abdominal pain—Vincristine—colon cancer	0.000205	0.00323	CcSEcCtD
Metolazone—Flatulence—Capecitabine—colon cancer	0.000204	0.00321	CcSEcCtD
Metolazone—Erectile dysfunction—Methotrexate—colon cancer	0.000204	0.00321	CcSEcCtD
Metolazone—Dysgeusia—Capecitabine—colon cancer	0.000203	0.00319	CcSEcCtD
Metolazone—Photosensitivity reaction—Methotrexate—colon cancer	0.000202	0.00318	CcSEcCtD
Metolazone—Back pain—Capecitabine—colon cancer	0.0002	0.00315	CcSEcCtD
Metolazone—Abdominal pain—Irinotecan—colon cancer	0.0002	0.00314	CcSEcCtD
Metolazone—Feeling abnormal—Fluorouracil—colon cancer	0.000199	0.00314	CcSEcCtD
Metolazone—Muscle spasms—Capecitabine—colon cancer	0.000199	0.00314	CcSEcCtD
Metolazone—Drowsiness—Methotrexate—colon cancer	0.000197	0.00311	CcSEcCtD
Metolazone—Stevens-Johnson syndrome—Methotrexate—colon cancer	0.000195	0.00308	CcSEcCtD
Metolazone—Vision blurred—Capecitabine—colon cancer	0.000195	0.00307	CcSEcCtD
Metolazone—Ill-defined disorder—Capecitabine—colon cancer	0.000192	0.00303	CcSEcCtD
Metolazone—Urticaria—Fluorouracil—colon cancer	0.000192	0.00303	CcSEcCtD
Metolazone—Anaemia—Capecitabine—colon cancer	0.000191	0.00301	CcSEcCtD
Metolazone—Hypersensitivity—Vincristine—colon cancer	0.000191	0.00301	CcSEcCtD
Metolazone—Malaise—Capecitabine—colon cancer	0.000187	0.00294	CcSEcCtD
Metolazone—Epistaxis—Methotrexate—colon cancer	0.000186	0.00293	CcSEcCtD
Metolazone—Vertigo—Capecitabine—colon cancer	0.000186	0.00293	CcSEcCtD
Metolazone—Hypersensitivity—Irinotecan—colon cancer	0.000186	0.00293	CcSEcCtD
Metolazone—Asthenia—Vincristine—colon cancer	0.000186	0.00293	CcSEcCtD
Metolazone—Syncope—Capecitabine—colon cancer	0.000186	0.00292	CcSEcCtD
Metolazone—Leukopenia—Capecitabine—colon cancer	0.000185	0.00292	CcSEcCtD
Metolazone—Agranulocytosis—Methotrexate—colon cancer	0.000184	0.0029	CcSEcCtD
Metolazone—Palpitations—Capecitabine—colon cancer	0.000183	0.00288	CcSEcCtD
Metolazone—Loss of consciousness—Capecitabine—colon cancer	0.000182	0.00287	CcSEcCtD
Metolazone—Asthenia—Irinotecan—colon cancer	0.000181	0.00285	CcSEcCtD
Metolazone—Cough—Capecitabine—colon cancer	0.000181	0.00285	CcSEcCtD
Metolazone—CA4—Metabolism—CHST5—colon cancer	0.000179	0.00186	CbGpPWpGaD
Metolazone—CA4—Metabolism—ODC1—colon cancer	0.000179	0.00186	CbGpPWpGaD
Metolazone—Hypertension—Capecitabine—colon cancer	0.000179	0.00282	CcSEcCtD
Metolazone—Hypersensitivity—Fluorouracil—colon cancer	0.000178	0.00281	CcSEcCtD
Metolazone—Diarrhoea—Vincristine—colon cancer	0.000177	0.00279	CcSEcCtD
Metolazone—Hepatitis—Methotrexate—colon cancer	0.000177	0.00279	CcSEcCtD
Metolazone—Chest pain—Capecitabine—colon cancer	0.000176	0.00278	CcSEcCtD
Metolazone—Arthralgia—Capecitabine—colon cancer	0.000176	0.00278	CcSEcCtD
Metolazone—Anxiety—Capecitabine—colon cancer	0.000176	0.00277	CcSEcCtD
Metolazone—Discomfort—Capecitabine—colon cancer	0.000174	0.00274	CcSEcCtD
Metolazone—Diarrhoea—Irinotecan—colon cancer	0.000173	0.00272	CcSEcCtD
Metolazone—Dry mouth—Capecitabine—colon cancer	0.000172	0.00272	CcSEcCtD
Metolazone—Dizziness—Vincristine—colon cancer	0.000171	0.0027	CcSEcCtD
Metolazone—Pruritus—Fluorouracil—colon cancer	0.000171	0.00269	CcSEcCtD
Metolazone—Erythema multiforme—Methotrexate—colon cancer	0.000167	0.00264	CcSEcCtD
Metolazone—Dizziness—Irinotecan—colon cancer	0.000167	0.00263	CcSEcCtD
Metolazone—Shock—Capecitabine—colon cancer	0.000166	0.00262	CcSEcCtD
Metolazone—Diarrhoea—Fluorouracil—colon cancer	0.000165	0.00261	CcSEcCtD
Metolazone—Thrombocytopenia—Capecitabine—colon cancer	0.000165	0.00261	CcSEcCtD
Metolazone—Tinnitus—Methotrexate—colon cancer	0.000165	0.0026	CcSEcCtD
Metolazone—Vomiting—Vincristine—colon cancer	0.000165	0.0026	CcSEcCtD
Metolazone—Rash—Vincristine—colon cancer	0.000163	0.00257	CcSEcCtD
Metolazone—Dermatitis—Vincristine—colon cancer	0.000163	0.00257	CcSEcCtD
Metolazone—Headache—Vincristine—colon cancer	0.000162	0.00256	CcSEcCtD
Metolazone—Anorexia—Capecitabine—colon cancer	0.000161	0.00254	CcSEcCtD
Metolazone—Vomiting—Irinotecan—colon cancer	0.00016	0.00253	CcSEcCtD
Metolazone—Dizziness—Fluorouracil—colon cancer	0.00016	0.00252	CcSEcCtD
Metolazone—Rash—Irinotecan—colon cancer	0.000159	0.00251	CcSEcCtD
Metolazone—Dermatitis—Irinotecan—colon cancer	0.000159	0.00251	CcSEcCtD
Metolazone—Chills—Methotrexate—colon cancer	0.000159	0.0025	CcSEcCtD
Metolazone—Headache—Irinotecan—colon cancer	0.000158	0.00249	CcSEcCtD
Metolazone—Nausea—Vincristine—colon cancer	0.000154	0.00243	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Capecitabine—colon cancer	0.000154	0.00242	CcSEcCtD
Metolazone—CA4—lymph node—colon cancer	0.000154	0.0201	CbGeAlD
Metolazone—Vomiting—Fluorouracil—colon cancer	0.000154	0.00242	CcSEcCtD
Metolazone—Insomnia—Capecitabine—colon cancer	0.000153	0.00241	CcSEcCtD
Metolazone—Rash—Fluorouracil—colon cancer	0.000152	0.0024	CcSEcCtD
Metolazone—Dermatitis—Fluorouracil—colon cancer	0.000152	0.0024	CcSEcCtD
Metolazone—Paraesthesia—Capecitabine—colon cancer	0.000152	0.00239	CcSEcCtD
Metolazone—Headache—Fluorouracil—colon cancer	0.000151	0.00239	CcSEcCtD
Metolazone—Dysgeusia—Methotrexate—colon cancer	0.000151	0.00238	CcSEcCtD
Metolazone—Nausea—Irinotecan—colon cancer	0.00015	0.00236	CcSEcCtD
Metolazone—Back pain—Methotrexate—colon cancer	0.000149	0.00235	CcSEcCtD
Metolazone—Dyspepsia—Capecitabine—colon cancer	0.000149	0.00234	CcSEcCtD
Metolazone—Decreased appetite—Capecitabine—colon cancer	0.000147	0.00231	CcSEcCtD
Metolazone—Fatigue—Capecitabine—colon cancer	0.000146	0.00229	CcSEcCtD
Metolazone—Vision blurred—Methotrexate—colon cancer	0.000145	0.00229	CcSEcCtD
Metolazone—CA9—Metabolism—ODC1—colon cancer	0.000145	0.0015	CbGpPWpGaD
Metolazone—CA9—Metabolism—CHST5—colon cancer	0.000145	0.0015	CbGpPWpGaD
Metolazone—Constipation—Capecitabine—colon cancer	0.000144	0.00228	CcSEcCtD
Metolazone—Pain—Capecitabine—colon cancer	0.000144	0.00228	CcSEcCtD
Metolazone—Nausea—Fluorouracil—colon cancer	0.000144	0.00226	CcSEcCtD
Metolazone—Ill-defined disorder—Methotrexate—colon cancer	0.000143	0.00225	CcSEcCtD
Metolazone—Anaemia—Methotrexate—colon cancer	0.000142	0.00224	CcSEcCtD
Metolazone—Feeling abnormal—Capecitabine—colon cancer	0.000139	0.00219	CcSEcCtD
Metolazone—Malaise—Methotrexate—colon cancer	0.000139	0.00219	CcSEcCtD
Metolazone—Vertigo—Methotrexate—colon cancer	0.000138	0.00218	CcSEcCtD
Metolazone—Gastrointestinal pain—Capecitabine—colon cancer	0.000138	0.00218	CcSEcCtD
Metolazone—Leukopenia—Methotrexate—colon cancer	0.000138	0.00217	CcSEcCtD
Metolazone—Cough—Methotrexate—colon cancer	0.000134	0.00212	CcSEcCtD
Metolazone—Urticaria—Capecitabine—colon cancer	0.000134	0.00211	CcSEcCtD
Metolazone—Abdominal pain—Capecitabine—colon cancer	0.000134	0.0021	CcSEcCtD
Metolazone—CA9—HIF-1-alpha transcription factor network—AKT1—colon cancer	0.000132	0.00137	CbGpPWpGaD
Metolazone—Arthralgia—Methotrexate—colon cancer	0.000131	0.00207	CcSEcCtD
Metolazone—Chest pain—Methotrexate—colon cancer	0.000131	0.00207	CcSEcCtD
Metolazone—Discomfort—Methotrexate—colon cancer	0.00013	0.00204	CcSEcCtD
Metolazone—Hypersensitivity—Capecitabine—colon cancer	0.000124	0.00196	CcSEcCtD
Metolazone—Thrombocytopenia—Methotrexate—colon cancer	0.000123	0.00194	CcSEcCtD
Metolazone—Asthenia—Capecitabine—colon cancer	0.000121	0.00191	CcSEcCtD
Metolazone—Anorexia—Methotrexate—colon cancer	0.00012	0.00189	CcSEcCtD
Metolazone—Pruritus—Capecitabine—colon cancer	0.00012	0.00188	CcSEcCtD
Metolazone—SLC12A3—Transmembrane transport of small molecules—ABCB1—colon cancer	0.000117	0.00122	CbGpPWpGaD
Metolazone—Diarrhoea—Capecitabine—colon cancer	0.000116	0.00182	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Methotrexate—colon cancer	0.000115	0.00181	CcSEcCtD
Metolazone—Insomnia—Methotrexate—colon cancer	0.000114	0.00179	CcSEcCtD
Metolazone—Paraesthesia—Methotrexate—colon cancer	0.000113	0.00178	CcSEcCtD
Metolazone—Somnolence—Methotrexate—colon cancer	0.000112	0.00176	CcSEcCtD
Metolazone—Dizziness—Capecitabine—colon cancer	0.000112	0.00176	CcSEcCtD
Metolazone—Dyspepsia—Methotrexate—colon cancer	0.000111	0.00174	CcSEcCtD
Metolazone—Decreased appetite—Methotrexate—colon cancer	0.000109	0.00172	CcSEcCtD
Metolazone—Fatigue—Methotrexate—colon cancer	0.000108	0.00171	CcSEcCtD
Metolazone—Pain—Methotrexate—colon cancer	0.000108	0.00169	CcSEcCtD
Metolazone—Vomiting—Capecitabine—colon cancer	0.000107	0.00169	CcSEcCtD
Metolazone—Rash—Capecitabine—colon cancer	0.000107	0.00168	CcSEcCtD
Metolazone—Dermatitis—Capecitabine—colon cancer	0.000106	0.00168	CcSEcCtD
Metolazone—Headache—Capecitabine—colon cancer	0.000106	0.00167	CcSEcCtD
Metolazone—Feeling abnormal—Methotrexate—colon cancer	0.000104	0.00163	CcSEcCtD
Metolazone—Gastrointestinal pain—Methotrexate—colon cancer	0.000103	0.00162	CcSEcCtD
Metolazone—Nausea—Capecitabine—colon cancer	0.0001	0.00158	CcSEcCtD
Metolazone—Urticaria—Methotrexate—colon cancer	9.99e-05	0.00157	CcSEcCtD
Metolazone—Abdominal pain—Methotrexate—colon cancer	9.94e-05	0.00157	CcSEcCtD
Metolazone—Hypersensitivity—Methotrexate—colon cancer	9.26e-05	0.00146	CcSEcCtD
Metolazone—Asthenia—Methotrexate—colon cancer	9.02e-05	0.00142	CcSEcCtD
Metolazone—Pruritus—Methotrexate—colon cancer	8.9e-05	0.0014	CcSEcCtD
Metolazone—Diarrhoea—Methotrexate—colon cancer	8.6e-05	0.00136	CcSEcCtD
Metolazone—Dizziness—Methotrexate—colon cancer	8.32e-05	0.00131	CcSEcCtD
Metolazone—Vomiting—Methotrexate—colon cancer	8e-05	0.00126	CcSEcCtD
Metolazone—Rash—Methotrexate—colon cancer	7.93e-05	0.00125	CcSEcCtD
Metolazone—Dermatitis—Methotrexate—colon cancer	7.92e-05	0.00125	CcSEcCtD
Metolazone—Headache—Methotrexate—colon cancer	7.88e-05	0.00124	CcSEcCtD
Metolazone—CA9—Cellular responses to stress—CDKN1A—colon cancer	7.59e-05	0.000788	CbGpPWpGaD
Metolazone—Nausea—Methotrexate—colon cancer	7.47e-05	0.00118	CcSEcCtD
Metolazone—CA9—Cellular responses to stress—EP300—colon cancer	7.22e-05	0.00075	CbGpPWpGaD
Metolazone—CA5A—Metabolism—ABCB1—colon cancer	6.85e-05	0.000712	CbGpPWpGaD
Metolazone—CA9—Cellular responses to stress—VEGFA—colon cancer	6.84e-05	0.00071	CbGpPWpGaD
Metolazone—CA5A—Metabolism—TYMS—colon cancer	6.73e-05	0.000699	CbGpPWpGaD
Metolazone—CA7—Metabolism—ABCB1—colon cancer	6.4e-05	0.000665	CbGpPWpGaD
Metolazone—CA5B—Metabolism—ABCB1—colon cancer	6.4e-05	0.000665	CbGpPWpGaD
Metolazone—CA5B—Metabolism—TYMS—colon cancer	6.28e-05	0.000653	CbGpPWpGaD
Metolazone—CA7—Metabolism—TYMS—colon cancer	6.28e-05	0.000653	CbGpPWpGaD
Metolazone—CA12—Metabolism—ABCB1—colon cancer	5.93e-05	0.000616	CbGpPWpGaD
Metolazone—CA12—Metabolism—TYMS—colon cancer	5.82e-05	0.000605	CbGpPWpGaD
Metolazone—CA9—Cellular responses to stress—TP53—colon cancer	5.16e-05	0.000537	CbGpPWpGaD
Metolazone—CA5A—Metabolism—PPARG—colon cancer	4.77e-05	0.000495	CbGpPWpGaD
Metolazone—CA4—Metabolism—ABCB1—colon cancer	4.73e-05	0.000491	CbGpPWpGaD
Metolazone—CA4—Metabolism—TYMS—colon cancer	4.64e-05	0.000482	CbGpPWpGaD
Metolazone—CA5B—Metabolism—PPARG—colon cancer	4.45e-05	0.000463	CbGpPWpGaD
Metolazone—CA7—Metabolism—PPARG—colon cancer	4.45e-05	0.000463	CbGpPWpGaD
Metolazone—CA12—Metabolism—PPARG—colon cancer	4.12e-05	0.000429	CbGpPWpGaD
Metolazone—CA9—Metabolism—ABCB1—colon cancer	3.82e-05	0.000397	CbGpPWpGaD
Metolazone—CA9—Metabolism—TYMS—colon cancer	3.75e-05	0.00039	CbGpPWpGaD
Metolazone—CA5A—Metabolism—PTGS2—colon cancer	3.75e-05	0.00039	CbGpPWpGaD
Metolazone—CA5B—Metabolism—PTGS2—colon cancer	3.5e-05	0.000364	CbGpPWpGaD
Metolazone—CA7—Metabolism—PTGS2—colon cancer	3.5e-05	0.000364	CbGpPWpGaD
Metolazone—CA4—Metabolism—PPARG—colon cancer	3.29e-05	0.000342	CbGpPWpGaD
Metolazone—CA12—Metabolism—PTGS2—colon cancer	3.24e-05	0.000337	CbGpPWpGaD
Metolazone—CA5A—Metabolism—EP300—colon cancer	3.12e-05	0.000324	CbGpPWpGaD
Metolazone—CA5B—Metabolism—EP300—colon cancer	2.91e-05	0.000303	CbGpPWpGaD
Metolazone—CA7—Metabolism—EP300—colon cancer	2.91e-05	0.000303	CbGpPWpGaD
Metolazone—CA12—Metabolism—EP300—colon cancer	2.7e-05	0.00028	CbGpPWpGaD
Metolazone—CA9—Metabolism—PPARG—colon cancer	2.66e-05	0.000276	CbGpPWpGaD
Metolazone—CA4—Metabolism—PTGS2—colon cancer	2.59e-05	0.000269	CbGpPWpGaD
Metolazone—CA5A—Metabolism—PIK3CA—colon cancer	2.31e-05	0.00024	CbGpPWpGaD
Metolazone—CA5B—Metabolism—PIK3CA—colon cancer	2.15e-05	0.000224	CbGpPWpGaD
Metolazone—CA7—Metabolism—PIK3CA—colon cancer	2.15e-05	0.000224	CbGpPWpGaD
Metolazone—CA4—Metabolism—EP300—colon cancer	2.15e-05	0.000224	CbGpPWpGaD
Metolazone—CA9—Metabolism—PTGS2—colon cancer	2.09e-05	0.000217	CbGpPWpGaD
Metolazone—CA12—Metabolism—PIK3CA—colon cancer	2e-05	0.000207	CbGpPWpGaD
Metolazone—CA5A—Metabolism—AKT1—colon cancer	1.89e-05	0.000196	CbGpPWpGaD
Metolazone—CA7—Metabolism—AKT1—colon cancer	1.76e-05	0.000183	CbGpPWpGaD
Metolazone—CA5B—Metabolism—AKT1—colon cancer	1.76e-05	0.000183	CbGpPWpGaD
Metolazone—CA9—Metabolism—EP300—colon cancer	1.74e-05	0.000181	CbGpPWpGaD
Metolazone—CA12—Metabolism—AKT1—colon cancer	1.63e-05	0.000169	CbGpPWpGaD
Metolazone—CA4—Metabolism—PIK3CA—colon cancer	1.59e-05	0.000165	CbGpPWpGaD
Metolazone—CA4—Metabolism—AKT1—colon cancer	1.3e-05	0.000135	CbGpPWpGaD
Metolazone—CA9—Metabolism—PIK3CA—colon cancer	1.29e-05	0.000134	CbGpPWpGaD
Metolazone—CA9—Metabolism—AKT1—colon cancer	1.05e-05	0.000109	CbGpPWpGaD
